Research programme: helix-based peptide therapeutics - Prism

Drug Profile

Research programme: helix-based peptide therapeutics - Prism

Latest Information Update: 26 Jul 2011

Price : $50

At a glance

  • Originator Commonwealth Biotechnologies
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 26 Jul 2011 No development reported - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 12 May 2011 Prism Pharmaceuticals has been acquired by Baxter International
  • 02 Jun 2006 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top